Vogenx (NASDAQ:VOGX) Stock Bumped Down to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of Vogenx (NASDAQ:VOGX) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

VOGX has been the subject of several other reports. Zacks Research upgraded shares of Vogenx to a “hold” rating in a research note on Monday, September 28th. Weiss Ratings assumed coverage on shares of Vogenx in a report on Monday, November 9th. They issued a “sell (e-)” rating on the stock. JonesTrading started coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price target for the company. Finally, WBB Securities started coverage on shares of Vogenx in a report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.50.

Vogenx Trading Down 13.0%

VOGX stock traded down $2.48 during midday trading on Friday, hitting $16.67. The stock had a trading volume of 94,312 shares, compared to its average volume of 98,963. The stock has a market cap of $247.55 million and a price-to-earnings ratio of -79.38. The stock’s 50-day moving average price is $22.03. Vogenx has a 52-week low of $12.95 and a 52-week high of $38.41.

Vogenx (NASDAQ:VOGX) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Equities research analysts expect that Vogenx will post -0.61 EPS for the current year.

About Vogenx

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.